Depression (Central Nervous System) - Drugs In Development, 2021

July 2021 | 862 pages | ID: D6D95743ABF3EN
Global Markets Direct

Abstracts

Depression (Central Nervous System) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Drugs In Development, 2021, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Depression - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 15, 46, 53, 9, 111, 35 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 15 and 7 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Depression - Overview
Depression - Therapeutics Development
Depression - Therapeutics Assessment
Depression - Companies Involved in Therapeutics Development
Depression - Drug Profiles
Depression - Dormant Projects
Depression - Discontinued Products
Depression - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Depression, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Depression - Pipeline by AbbVie Inc, 2021
Depression - Pipeline by Adamed Sp zoo, 2021
Depression - Pipeline by Adare Pharma Solutions, 2021
Depression - Pipeline by Addex Therapeutics Ltd, 2021
Depression - Pipeline by Aision Biotechnologies Inc, 2021
Depression - Pipeline by Alar Pharmaceuticals Inc, 2021
Depression - Pipeline by Alexza Pharmaceuticals Inc, 2021
Depression - Pipeline by Alkermes Plc, 2021
Depression - Pipeline by Alzamend Neuro Inc, 2021
Depression - Pipeline by Amorsa Therapeutics Inc, 2021
Depression - Pipeline by Anavex Life Sciences Corp, 2021
Depression - Pipeline by Ancora Bio Inc, 2021
Depression - Pipeline by Angelini Spa, 2021
Depression - Pipeline by Antheia Inc, 2021
Depression - Pipeline by Asulon Therapeutics Inc, 2021
Depression - Pipeline by Atai Life Sciences BV, 2021
Depression - Pipeline by Athira Pharma Inc, 2021
Depression - Pipeline by Avanir Pharmaceuticals Inc, 2021
Depression - Pipeline by Avicanna Inc, 2021
Depression - Pipeline by Axsome Therapeutics Inc, 2021
Depression - Pipeline by Azevan Pharmaceuticals Inc, 2021
Depression - Pipeline by Baergic Bio Inc, 2021
Depression - Pipeline by Beloteca Inc, 2021
Depression - Pipeline by Benuvia Therapeutics Inc, 2021
Depression - Pipeline by Better Life Pharmaceuticals Inc, 2021
Depression - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021
Depression - Pipeline by BioXcel Therapeutics Inc, 2021
Depression - Pipeline by Blackthorn Therapeutics Inc, 2021
Depression - Pipeline by Blue Oak Pharmaceuticals Inc, 2021
Depression - Pipeline by Boehringer Ingelheim International GmbH, 2021
Depression - Pipeline by Braxia Scientific Corp, 2021
Depression - Pipeline by Bright Minds Biosciences Inc, 2021
Depression - Pipeline by Brii Biosciences Ltd, 2021
Depression - Pipeline by Bristol Myers Squibb Co, 2021
Depression - Pipeline by Calico Life Sciences LLC, 2021
Depression - Pipeline by Camino Pharma LLC, 2021
Depression - Pipeline by Cellix Bio Pvt Ltd, 2021
Depression - Pipeline by Celon Pharma SA, 2021
Depression - Pipeline by Cerevel Therapeutics Holdings Inc, 2021
Depression - Pipeline by Intas Pharmaceuticals Ltd, 2021
Depression - Pipeline by IntelGenx Corp, 2021
Depression - Pipeline by Intra-Cellular Therapies Inc, 2021
Depression - Pipeline by INVENT Pharmaceuticals Inc, 2021
Depression - Pipeline by iX Biopharma Ltd, 2021
Depression - Pipeline by Jazz Pharmaceuticals Plc, 2021
Depression - Pipeline by Jiangsu Gibel Pharmaceutical Co Ltd, 2021
Depression - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2021
Depression - Pipeline by Jiangsu Nhwa Pharmaceutical Co Ltd, 2021
Depression - Pipeline by Jina Pharmaceuticals Inc, 2021
Depression - Pipeline by Johnson & Johnson, 2021
Depression - Pipeline by Kissei Pharmaceutical Co Ltd, 2021
Depression - Pipeline by Klaria Pharma Holding AB, 2021
Depression - Pipeline by Korea Pharma Co Ltd, 2021
Depression - Pipeline by Krenitsky Pharmaceuticals Inc, 2021
Depression - Pipeline by Kures Inc, 2021
Depression - Pipeline by Lactocore Inc, 2021
Depression - Pipeline by LB Pharmaceuticals Inc, 2021
Depression - Pipeline by Lead Discovery Center GmbH, 2021
Depression - Pipeline by Phytecs, 2021
Depression - Pipeline by PNB Vesper Life Science Pvt Ltd, 2021
Depression - Pipeline by Praxis Precision Medicines Inc, 2021
Depression - Pipeline by Primetime Life Sciences LLC, 2021
Depression - Pipeline by Protagenic Therapeutics Inc, 2021
Depression - Pipeline by Prous Institute for Biomedical Research SA, 2021
Depression - Pipeline by Psirenity Inc, 2021
Depression - Pipeline by Psy Therapeutics Inc, 2021
Depression - Pipeline by PsyBio Therapeutics Corp, 2021
Depression - Pipeline by Relmada Therapeutics Inc, 2021
Depression - Pipeline by Repurposed Therapeutics Inc, 2021
Depression - Pipeline by Reset Pharmaceuticals Inc, 2021
Depression - Pipeline by Reven Pharmaceuticals Inc, 2021
Depression - Pipeline by Reviva Pharmaceuticals Inc, 2021
Depression - Pipeline by Revive Therapeutics Ltd, 2021
Depression - Pipeline by Revixia Life Sciences Inc, 2021
Depression - Pipeline by Richter Gedeon Nyrt, 2021
Depression - Pipeline by Rugen Therapeutics R&D (Shanghai) Co Ltd, 2021
Depression - Pipeline by Sage Therapeutics Inc, 2021
Depression - Pipeline by Sansero Life Sciences Inc, 2021
Depression - Pipeline by Seed Health Inc, 2021
Depression - Pipeline by Seelos Therapeutics, Inc., 2021
Depression - Pipeline by Shanghai SIMR Biotech Co Ltd, 2021
Depression - Pipeline by Shanghai Synergy Pharmaceutical Sciences Co Ltd, 2021
Depression - Pipeline by Shanghai Zhimeng Biopharma Inc, 2021
Depression - Pipeline by Shenox Pharmaceuticals LLC, 2021
Depression - Pipeline by Siragen Pharmaceuticals Inc, 2021
Depression - Pipeline by Sirtsei Pharmaceuticals Inc, 2021
Depression - Pipeline by SK Biopharmaceuticals Co Ltd, 2021
Depression - Pipeline by Small Pharma Inc, 2021
Depression - Pipeline by Sound Pharmaceuticals Inc, 2021
Depression - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021
Depression - Pipeline by Sun Pharma Advanced Research Company Ltd, 2021
Depression - Pipeline by Sunovion Pharmaceuticals Inc, 2021
Depression - Pipeline by Supernus Pharmaceuticals Inc, 2021
Depression - Pipeline by Suven Life Sciences Ltd, 2021
Depression - Pipeline by SyneuRx International Corp, 2021
Depression - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
Depression - Pipeline by Tasly Pharmaceutical Group Co Ltd, 2021
Depression - Pipeline by Techfields Pharma Co Ltd, 2021
Depression - Pipeline by Tempero Bio, 2021
Depression - Pipeline by Terran Biosciences Inc, 2021
Depression - Pipeline by Therapeutic Solutions International Inc, 2021
Depression - Pipeline by Tonix Pharmaceuticals Holding Corp, 2021
Depression - Pipeline by Trevena Inc, 2021
Depression - Pipeline by Vanda Pharmaceuticals Inc, 2021
Depression - Pipeline by Viatris Inc, 2021
Depression - Pipeline by Viridia Life Sciences, 2021
Depression - Pipeline by VistaGen Therapeutics Inc, 2021
Depression - Pipeline by Vivozon Inc, 2021
Depression - Pipeline by Wake Network Inc, 2021
Depression - Pipeline by Whan In Pharm Co Ltd, 2021
Depression - Pipeline by Xenon Pharmaceuticals Inc, 2021
Depression - Pipeline by XWPharma Ltd, 2021
Depression - Pipeline by Yantai YenePharma Co Ltd, 2021
Depression - Pipeline by Yungjin Pharm Co Ltd, 2021
Depression - Pipeline by Zelira Therapeutics Ltd, 2021
Depression - Pipeline by Zysis Ltd, 2021
Depression - Dormant Projects, 2021
Depression - Dormant Projects, 2021 (Contd..1)
Depression - Dormant Projects, 2021 (Contd..2)
Depression - Dormant Projects, 2021 (Contd..3)
Depression - Dormant Projects, 2021 (Contd..4)
Depression - Dormant Projects, 2021 (Contd..5)
Depression - Dormant Projects, 2021 (Contd..6)
Depression - Dormant Projects, 2021 (Contd..7)
Depression - Dormant Projects, 2021 (Contd..8)
Depression - Dormant Projects, 2021 (Contd..9)
Depression - Dormant Projects, 2021 (Contd..10)
Depression - Dormant Projects, 2021 (Contd..11)
Depression - Dormant Projects, 2021 (Contd..12)
Depression - Dormant Projects, 2021 (Contd..13)
Depression - Dormant Projects, 2021 (Contd..14)
Depression - Dormant Projects, 2021 (Contd..15)
Depression - Dormant Projects, 2021 (Contd..16)
Depression - Dormant Projects, 2021 (Contd..17)
Depression - Dormant Projects, 2021 (Contd..18)
Depression - Discontinued Products, 2021
Depression - Discontinued Products, 2021 (Contd..1)
Depression - Discontinued Products, 2021 (Contd..2)
Depression - Discontinued Products, 2021 (Contd..3)
Depression - Discontinued Products, 2021 (Contd..4)

List Of Figures

LIST OF FIGURES

Number of Products under Development for Depression, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021